Overview

Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The aim of this placebo-controlled randomized study was to evaluate the efficacy of Circadin™ 2 mg in improving total night sleep duration and stabilizing the circadian clock phase in totally blind subjects with non-24 hour sleep-wake disorder.
Phase:
Phase 2
Details
Lead Sponsor:
Neurim Pharmaceuticals Ltd.
Treatments:
Melatonin